Theranostic application of 131I-labeled anti-glypican-3 antibody for targeted radioimmunotherapy in hepatocellular carcinoma

Key Points

• Treatment shows significant tumor regression in hepatocellular carcinoma patients, indicating potential effectiveness.
• Key evidence includes a 40% reduction in tumor size after 3 months of therapy, along with minimal side effects.
• Treatment involves the use of 131I-labeled anti-glypican-3 antibodies to specifically target cancer cells and deliver radiation.
• This highlights the need for expanded studies to confirm long-term outcomes and safety in diverse populations.